Navigation Links
Neovasc Announces Agreement With LeMaitre Vascular for Exclusive Distribution Rights to its Biological Vascular Strips
Date:1/26/2009

    --Vascular Device Leader LeMaitre Vascular to Distribute Neovasc's
    Biological Vascular Strips in the U.S. and Europe, With Option to
    Purchase the Product Line--

VANCOUVER, Jan. 26 /PRNewswire-FirstCall/ - Neovasc Inc. (TSXV: NVC), a new specialty vascular device company, today announced that it has entered into a distribution agreement with LeMaitre Vascular, Inc. (Nasdaq: LMAT) for Neovasc's biological vascular strip for use in vascular surgery procedures. Under the terms of the seven-year agreement, LeMaitre Vascular has exclusive rights to market and sell certain sizes of Neovasc's tissue patch products used for vascular surgery in the United States and Europe.

"LeMaitre Vascular has a well-earned reputation among vascular surgeons for technical innovation and strong sales and customer support, and we are delighted that they will be distributing our vascular strip products" said Alexei Marko, chief executive officer of Neovasc. "The performance and exceptional handling characteristics of our tissue products make them appropriate for a number of vascular applications, including carotid endarterectomy, which should complement LeMaitre Vascular's gold-standard Pruitt-Inahara Carotid Shunt line. We are very pleased that this superior product will now benefit from the expertise and reach of the high quality sales and marketing professionals at LeMaitre Vascular."

The Neovasc biologic vascular strip is derived from bovine pericardial tissue, a biocompatible and versatile material that has been shown to have exceptional strength and handling characteristics, allowing surgeons the flexibility to implant with ease. This biocompatible material also has a 20-year safety record of use in cardiac indications. The strip is well-suited for use in carotid endarterectomy as well as other precision vascular applications.

Under the terms of the agreement, LeMaitre Vascular has the option to purchase the biologic vascular strip product technology from Neovasc after five years. LeMaitre Vascular's use of the technology after acquisition would be limited to the manufacture of strips for use in vascular procedures, and Neovasc would retain the rights to all other applications of its biological patch technology. Further details of the agreement were not disclosed.

About LeMaitre Vascular

LeMaitre Vascular is a provider of devices for the treatment of peripheral vascular disease. The company develops, manufactures and markets disposable and implantable vascular devices to address the needs of vascular surgeons. The company's devices are used to treat peripheral vascular disease; a condition that the company estimates affects more than 20 million people worldwide. Well-known to vascular surgeons, the company's diversified product portfolio consists of brand name devices that are used in arteries and veins outside of the heart including the Expandable LeMaitre Valvulotome, the Pruitt-Inahara Carotid Shunt and the newly-introduced TAArget Thoracic Stent Graft. For more information, visit http://www.lemaitre.com.

About Neovasc Inc

Neovasc Inc. (formerly Medical Ventures Corp.), is a new specialty vascular device company that develops, manufactures and markets medical devices for the rapidly growing vascular and surgical marketplace. Neovasc is comprised of the former Medical Ventures Corp., Neovasc Medical Ltd. and B-Balloon Ltd. The company's current products include, Metricath(R) for intravascular measurement and PeriPatch(TM) surgical tissue and staple line reinforcement products. Neovasc has a development pipeline of innovative new products, and provides contract medical device development and manufacturing services. For more information, visit: www.neova6sc.com.

Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates," "believes," "may," "continues," "estimates," "expects," and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which Neovasc operates; history of losses and lack of and uncertainty of revenues, ability to obtain required financing, receipt of regulatory approval of product candidates, ability to properly integrate newly acquired businesses, technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against Neovasc; and other factors referenced in the Neovasc's filings with Canadian securities regulators. Although Neovasc believes that expectations conveyed by the forward-looking statements are reasonable based on the information available to it on the date such statements were made, no assurances can be given as to the future results, approvals or achievements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Neovasc does not assume the obligation to update any forward-looking statements except as otherwise required by applicable law.


'/>"/>
SOURCE Neovasc Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options
2. Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results
3. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
4. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
5. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
6. HEI, Inc. Announces Sale of RFID Division Assets
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
9. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
10. Brooke Franchise Corporation Announces Selected July Results
11. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... , ... Sharon Kleyne, host of the nationally syndicated radio program, The Sharon ... America, declared on her radio program in November 2016 the need to educate people ... attack leaders in corporate America, they are trying to take advantage of successful algorithms ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... Facial plastic ... this holiday season by donating a portion of proceeds to two local organizations: North ... Chicago Animal Control & Friends is a team of authorized and trained volunteers ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... is condemning "scam operations" carried out by unethical locksmith companies and is urging ... to a halt. According to Texas Premier Locksmith, these fraudulent locksmith services take ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... The medical ... holidays and winter seasons. One major study analyzing heart attacks among 138,602 people ... August of a given year. We would all agree of course–no time of year ...
(Date:12/7/2016)... Ohio (PRWEB) , ... December 07, 2016 , ... ... in the 2016 BOC Business Brilliance Awards under the Best New Product Launch ... and results achieved through user experience. , BOC Global Events & Training Group ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... 6, 2016 Anaplastic Oligoastrocytoma - Pipeline ... Direct,s latest Pharmaceutical and Healthcare disease pipeline guide ... an overview of the Anaplastic Oligoastrocytoma (Oncology) pipeline ... that forms when two types of cells in ... in number to form a mass. These brain ...
(Date:12/6/2016)...   AlloSource , one of the nation,s ... soft-tissue allografts for use in surgical procedures, recognized ... being named to the Board of Examiners for ... the Commerce Department,s National Institute of Standards and ... excellence. The Baldrige Award is the nation,s highest ...
(Date:12/6/2016)...  BTL Aesthetics today announced the release of ... ME device was effectively redesigned for more efficient, ... tissue. The result: Significantly better outcomes in abdominal ... ME versus BTL Vanquish. "We are ... patients with the most highly-advanced devices on the ...
Breaking Medicine Technology: